Portal Diabetes Receives FDA Breakthrough Designation for Implantable Insulin Pump System
核心洞察
Portal Diabetes (搜索) has received FDA breakthrough device designation for its implantable insulin pump system, facilitating priority regulatory engagement and potential Medicare coverage acceleration.
The company has initiated a Phase I study of its temperature-stable insulin, with the first two patients receiving Portal Insulin (搜索) injections into the intraperitoneal space at a San Diego clinical site.
The Portal Pump (搜索) system aims to provide a functional cure for type 1 diabetes (搜索) by combining implantable pump technology, continuous glucose monitoring, and concentrated insulin for fully automated delivery.
Portal Diabetes (搜索) has achieved two significant regulatory and clinical milestones in its quest to develop what the company calls a "functional cure" for type 1 diabetes (搜索). The Westfield, Indiana-based company announced it has received FDA breakthrough device designation for its implantable insulin pump system, known as the Portal Pump (搜索), while simultaneously initiating a Phase I study of its proprietary temperature-stable insulin formulation.
FDA Breakthrough Designation Opens Regulatory Pathway
The breakthrough device designation represents a critical regulatory achievement that will facilitate priority interactions with the FDA as Portal Diabetes (搜索) advances through clinical trials and regulatory submissions. This designation also establishes eligibility for the Transitional Coverage for Emerging Technologies (TCET) pathway, which can expedite Medicare coverage once the device receives FDA approval as a breakthrough technology.
The Portal Pump (搜索) system is designed to address the complex management challenges faced by people with type 1 diabetes (搜索) by combining three key components: an implantable pump that delivers insulin directly into the abdomen, continuous glucose monitoring technology, and concentrated insulin to create a fully automated insulin delivery system.
First Clinical Milestone Achieved
Under an investigational new drug (IND) application, Portal Diabetes (搜索) has administered Portal Insulin (搜索) to its first two patients through injection into the intraperitoneal space at a clinical center in San Diego, California. This represents a major milestone in the development of the Portal Pump (搜索) Combination System, marking the first clinical use of the company's temperature-stable insulin formulation.
"We believe patients will achieve much better glycemic control for a dramatically reduced mental burden with the Portal Pump (搜索)," said Stacy Chambliss, CEO of Portal Diabetes (搜索). "No more meal announcements, no more exercise announcements, no more night wakings; that is our goal. Step by step, we are working diligently to bring long-awaited technology to patients living with type 1 diabetes (搜索)."
Development Timeline and Regulatory Status
Clinical trials of the complete combination system are expected to commence around the fourth quarter of 2027. The company is currently seeking endocrinologists, surgeons, and clinical sites interested in participating in future trials.
Currently, the Portal Pump (搜索) is not authorized for sale or investigational use in the United States. Portal Insulin (搜索) remains under IND status and is not commercially available in the country. The company's approach represents a significant departure from current diabetes management approaches by leveraging physiologic delivery of insulin directly to the abdomen, potentially eliminating many of the daily management burdens associated with type 1 diabetes (搜索).
The breakthrough designation and successful initiation of clinical testing represent important steps toward what Portal Diabetes (搜索) envisions as a transformative approach to type 1 diabetes (搜索) management, potentially offering patients improved glycemic control with reduced daily management requirements.